Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would drugmakers agree to reduce their prices right away?

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new class of weight-loss drugs.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are driving down grocery spending, according to a new study from Cornell’s SC Johnson College of Business and consumer data firm Numerator.

Higher-income households with at least one user of GLP-1 class of weight loss drugs cut their grocery spending by nearly 9%, a recent study based on data from the market research firm Numerator indicates.